AKRO logo

Akero Therapeutics (AKRO) Company Overview

Profile

Full Name:

Akero Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 20, 2019

Indexes:

Not included

Website:

http://akerotx.com

Description:

Akero Therapeutics Inc. is a company specializing in cardiometabolic non-alcoholic steatohepatitis (NASH). The company focuses on developing drugs aimed at restoring metabolic balance and improving the overall health of patients with NASH. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to target the processes underlying the pathogenesis of NASH, with the potential to restore healthy liver fat metabolism, reduce hepatocyte stress, alleviate inflammation, and eliminate fibrosis. Efruxifermin is being developed in a separate cohort studying the treatment of patients with compensated liver cirrhosis (F4).

Key Details

Price

$41.35

Market Cap

$3.29 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$3.75(-29.76% YoY)

PE Ratio

-

Annual ROE

-33.60%

Annual Debt To Equity

0.05

Beta

0.71

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Feb 28, 2025

Recent annual earnings:

Feb 28, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Mar 3, 25 HC Wainwright & Co.
Buy
Jan 31, 25 UBS
Buy
Jan 30, 25 B of A Securities
Buy
Jan 27, 25 HC Wainwright & Co.
Buy
Jan 16, 25 HC Wainwright & Co.
Buy
Nov 18, 24 HC Wainwright & Co.
Buy
Nov 18, 24 Citigroup
Buy
Nov 11, 24 HC Wainwright & Co.
Buy
Aug 12, 24 HC Wainwright & Co.
Buy
Jun 20, 24 Cantor Fitzgerald
Overweight

Screeners with AKRO included

Growing Shares Outstanding
Mid cap stocks
US stocks
Biggest stock losers today
Most recommended stocks
Best performing stocks last 3 months
Best performing stocks last 5 years
Stocks above SMA 50
Stocks below analysts price target
Healthcare sector

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$41.35
AKRO price is $41.35

Price All-time High

$57.88
AKRO price is currently -28.56% below its historical high of $57.88

Price Analysts Target

$75.00
AKRO price is currently -44.87% lower than the consensus analysts' forecast

Price Most Recent Change

-6.55%
AKRO price was down -6.55% on Mar 7, 2025

Price YTD Change

+51.74%
AKRO price is up +51.74% since January 1st

Price 3-Year Change

+174.2%
AKRO price is up +174.2% over the past 3 years

Market cap

Market Cap

$3.29 B
AKRO market capitalization is $3.29 billion

Market Cap 3-Year Change

+523.55%
AKRO market capitalization is up +523.55% over the past 3 years

Market Cap All-time High

$4.33 B
AKRO market capitalization is currently -24.03% below its historical high of $4.33 billion

Market Cap Sector Rank

86.5%
AKRO market capitalization is higher than 86.5% of companies in Healthcare sector

Technical

Beta

0.71
AKRO beta is 0.71

200-day SMA

$30.25
AKRO price is currently +36.70% above its 200-day simple moving average

14-day RSI

40.49
AKRO 14-day relative strength index is 40.49

30-day Relative Volume

0.53
AKRO 30-day relative volume is 0.53

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

-
AKRO annual revenue value is unknown

Annual Revenue Analysts Estimate

-
AKRO annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

-
AKRO annual revenue 1-year change is unknown

Annual Revenue Sector Rank

-
AKRO annual revenue is unknown

Profit

Annual Gross Profit

-
AKRO annual gross profit value is unknown

Annual Gross Margin

-
AKRO annual gross profit margin value is unknown

Annual Operating Profit

-$285.42 M
AKRO annual operating income is -$285.42 million

Annual Operating Margin

-
AKRO annual operating profit margin value is unknown

Annual Net Income

-$252.06 M
AKRO annual net profit is -$252.06 million

Annual Net Margin

-
AKRO annual net profit margin value is unknown

EPS

Annual EPS

-$3.75
AKRO annual earnings per share is -$3.75

Annual EPS Analysts Estimate

-$4.03
AKRO annual earnings per share is currently -6.96% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

-29.76%
AKRO annual earnings per share is down -29.76% year-on-year

Annual EPS Sector Rank

27.12%
AKRO annual earnings per share is higher than 27.12% of companies in Healthcare sector

ROA & ROE

Annual ROA

-30.52%
AKRO annual return on assets is -30.52%

Annual ROE

-33.60%
AKRO annual return on equity is -33.60%

EBIT & EBITDA

Annual EBIT

-$247.39 M
AKRO annual earnings before interest & taxes is -$247.39 million

Annual EBITDA

-$247.37 M
AKRO annual EBITDA is -$247.37 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
AKRO price to earnings ratio value is unknown

PE Ratio Sector Rank

-
AKRO price to earnings ratio is unknown

PB Ratio

PB Ratio

4.39
AKRO price to book ratio is 4.39

PB Ratio Sector Rank

80.07%
AKRO price to book ratio is higher than 80.07% of companies in Healthcare sector

PS Ratio

PS Ratio

-
AKRO price to sales ratio value is unknown

PS Ratio Sector Rank

-
AKRO price to sales ratio is unknown

Enterprise value

Enterprise Value

$2.99 B
AKRO enterprise value is $2.99 billion

Enterprise Value Sector Rank

84.48%
AKRO enterprise value is higher than 84.48% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-12.08
AKRO EV/EBITDA is -12.08

EV/EBITDA Sector Rank

10.68%
AKRO EV/EBITDA is higher than 10.68% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

19.38
AKRO annual current ratio is 19.38

Annual Quick Ratio

-
AKRO annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.05
AKRO annual debt to equity ratio is 0.05

Annual Interest Coverage Ratio

-53.00
AKRO annual interest coverage ratio is -53.00

Risk & Stability

Piotroski F-Score

-
AKRO piotroski f-score value is unknown

Altman Z-Score

-
AKRO altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$825.89 M
AKRO annual total assets is $825.89 million

Annual Non Current Assets

$55.51 M
AKRO annual long term assets is $55.51 million

Annual Current Assets

$770.38 M
AKRO annual total current assets is $770.38 million

Annual Cash & Cash Equivalents

$340.24 M
AKRO annual cash & cash equivalents is $340.24 million

Equity

Annual Book Value

$750.11 M
AKRO annual book value is $750.11 million

Annual Working Capital

$730.63 M
AKRO annual working capital is $730.63 million

Liabilities

Annual Total Liabilities

$75.77 M
AKRO annual total liabilities is $75.77 million

Annual Total Long Term Liabilities

$36.02 M
AKRO annual total long term liabilities is $36.02 million

Annual Current Liabilities

$39.75 M
AKRO annual total current liabilities is $39.75 million

Annual Accounts Payable

$9.03 M
AKRO annual accounts payable is $9.03 million

Debt

Annual Total Debt

$36.46 M
AKRO annual total debt is $36.46 million

Annual Total Debt 1-Year Change

+38.59%
AKRO annual total debt is up +38.59% year-on-year

Annual Long Term Debt

$35.83 M
AKRO annual long term debt is $35.83 million

Annual Short Term Debt

$631.00 K
AKRO annual short term debt is $631.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$285.42 M
AKRO annual total expenses is $285.42 million

Annual Operating Expenses

$285.42 M
AKRO annual total operating expenses is $285.42 million

Annual Cost Of Goods Sold

-
AKRO annual cost of goods sold value is unknown

Annual SGA

$37.93 M
AKRO annual SGA is $37.93 million

Annual D&A

$18.00 K
AKRO annual depreciation & amortization is $18.00 thousand

Annual Interest Expense

$4.67 M
AKRO annual interest expense is $4.67 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$230.11 M
AKRO annual cash flow from operations is -$230.11 million

Annual CFO 1-Year Change

-58.29%
AKRO annual cash flow from operations is down -58.29% year-on-year

Annual CFI

-$109.71 M
AKRO annual cash flow from investing activities is -$109.71 million

Annual CFI 1-Year Change

+50.94%
AKRO annual cash flow from investing activities is up +50.94% year-on-year

Annual CFF

$445.85 M
AKRO annual cash flow from financing activities is $445.85 million

Annual CFF 1-Year Change

+26.19%
AKRO annual cash flow from financing activities is up +26.19% year-on-year

Free CashFlow

Annual FCF

-$231.11 M
AKRO annual free cash flow is -$231.11 million

Annual FCF 1-Year Change

-58.98%
AKRO annual free cash flow is down -58.98% year-on-year

CAPEX

Annual CAPEX

-
AKRO annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
AKRO annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

PRCT logo
PROCEPT BioRobotics (PRCT)
VKTX logo
Viking Therapeutics (VKTX)
XRAY logo
DENTSPLY SIRONA (XRAY)
SRRK logo
Scholar Rock Holding (SRRK)
IRTC logo
iRhythm Technologies (IRTC)
ALVO logo
Alvotech (ALVO)
APLS logo
Apellis Pharmaceuticals (APLS)
MRUS logo
Merus NV (MRUS)
IMVT logo
Immunovant (IMVT)

FAQ

  • What is the ticker symbol for Akero Therapeutics?
  • Does Akero Therapeutics pay dividends?
  • What sector is Akero Therapeutics in?
  • What industry is Akero Therapeutics in?
  • What country is Akero Therapeutics based in?
  • When did Akero Therapeutics go public?
  • Is Akero Therapeutics in the S&P 500?
  • Is Akero Therapeutics in the NASDAQ 100?
  • Is Akero Therapeutics in the Dow Jones?
  • When was Akero Therapeutics's last earnings report?
  • When does Akero Therapeutics report earnings?
  • Should I buy Akero Therapeutics stock now?

What is the ticker symbol for Akero Therapeutics?

The ticker symbol for Akero Therapeutics is NASDAQ:AKRO

Does Akero Therapeutics pay dividends?

No, Akero Therapeutics does not pay dividends

What sector is Akero Therapeutics in?

Akero Therapeutics is in the Healthcare sector

What industry is Akero Therapeutics in?

Akero Therapeutics is in the Biotechnology industry

What country is Akero Therapeutics based in?

Akero Therapeutics is headquartered in United States

When did Akero Therapeutics go public?

Akero Therapeutics's initial public offering (IPO) was on June 20, 2019

Is Akero Therapeutics in the S&P 500?

No, Akero Therapeutics is not included in the S&P 500 index

Is Akero Therapeutics in the NASDAQ 100?

No, Akero Therapeutics is not included in the NASDAQ 100 index

Is Akero Therapeutics in the Dow Jones?

No, Akero Therapeutics is not included in the Dow Jones index

When was Akero Therapeutics's last earnings report?

Akero Therapeutics's most recent earnings report was on Feb 28, 2025

When does Akero Therapeutics report earnings?

The next expected earnings date for Akero Therapeutics is May 9, 2025

Should I buy Akero Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions